A Study Comparing Radiofrequency Ablation and Hepatic Resection for Hepatocellular Carcinoma
Not Applicable
Terminated
- Conditions
- Carcinoma, Hepatocellular
- Registration Number
- NCT02482909
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
The purpose of this prospective randomized study is to compare the efficacy and safety of radiofrequency ablation and hepatic resection for small hepatocellular carcinomas with very homogeneous underlying conditions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 68
Inclusion Criteria
- Age between 20 and 70 years
- Child-Pugh class A (score 5-6)
- Single hepatocellular carcinoma
- Maximal diameter of the tumor from 2 to 4 cm when measured on MRI or CT (The diameter on MRI was measured prior to that on CT)
- No previous treatment
- Platelet count > 80,000/mm3
Exclusion Criteria
- HCC abutting main hepatic veins or the first branches of the main portal vein
- HCC abutting vessels ≥ 0.5 cm
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method The patient survival From the intervention up to 5 years or until the death of the participant whichever came first
- Secondary Outcome Measures
Name Time Method The disease-free survival From the intervention up to 5 years or until hepatocellular carcinoma recurrence whichever came first
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are involved in tumor cell destruction via radiofrequency ablation versus hepatic resection in NCT02482909?
How does radiofrequency ablation compare to hepatic resection in 5-year overall survival for single small HCC with homogeneous cirrhosis?
Which biomarkers correlate with recurrence-free survival after RFA or resection in NCT02482909 hepatocellular carcinoma patients?
What are the management strategies for post-RFA thermal injury versus post-resection complications in NCT02482909 HCC cohort?
Are there adjuvant therapies synergizing with RFA or hepatic resection for early-stage HCC in the context of NCT02482909 findings?